JP2021529539A5 - - Google Patents
Info
- Publication number
- JP2021529539A5 JP2021529539A5 JP2021500042A JP2021500042A JP2021529539A5 JP 2021529539 A5 JP2021529539 A5 JP 2021529539A5 JP 2021500042 A JP2021500042 A JP 2021500042A JP 2021500042 A JP2021500042 A JP 2021500042A JP 2021529539 A5 JP2021529539 A5 JP 2021529539A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- isolated nucleic
- amino acid
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692609P | 2018-06-29 | 2018-06-29 | |
| US62/692,609 | 2018-06-29 | ||
| PCT/US2019/040185 WO2020006568A1 (en) | 2018-06-29 | 2019-07-01 | Cd6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529539A JP2021529539A (ja) | 2021-11-04 |
| JP2021529539A5 true JP2021529539A5 (cg-RX-API-DMAC7.html) | 2022-07-08 |
| JP7376564B2 JP7376564B2 (ja) | 2023-11-08 |
Family
ID=67587926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500042A Active JP7376564B2 (ja) | 2018-06-29 | 2019-07-01 | 特定の自己免疫疾患を治療するためのｃｄ６標的キメラ抗原受容体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12281151B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4706679A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7376564B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN112638478B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019295855B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3061216T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020006568A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12281151B2 (en) | 2018-06-29 | 2025-04-22 | City Of Hope | CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders |
| WO2021138454A1 (en) * | 2019-12-30 | 2021-07-08 | City Of Hope | Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers |
| US20250161360A1 (en) * | 2022-05-10 | 2025-05-22 | Yale University | Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8426467D0 (en) | 1984-10-19 | 1984-11-28 | Technology Licence Co Ltd | Monoclonal antibodies |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| CU22584A1 (es) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis |
| HK1044159A1 (zh) | 1998-12-01 | 2002-10-11 | 蛋白质设计实验室股份有限公司 | 抗γ-干扰素的人化抗体 |
| WO2009113083A1 (en) | 2008-03-14 | 2009-09-17 | Biocon Limited | A monoclonal antibody and a method thereof |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| EP3024485B1 (en) | 2013-07-23 | 2020-11-18 | Biocon Limited | Use of a cd6 binding partner and method based thereon |
| BR112017005631A2 (pt) | 2014-09-19 | 2018-06-26 | City Of Hope | células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2 |
| WO2016179319A1 (en) * | 2015-05-04 | 2016-11-10 | Cellerant Therapeutics, Inc. | Chimeric antigen receptors with ctla4 signal transduction domains |
| EP3842448A1 (en) | 2015-05-15 | 2021-06-30 | City of Hope | Chimeric antigen receptor compositions |
| US10562975B2 (en) * | 2016-06-15 | 2020-02-18 | The Regents Of The University Of Michigan | CD6 antibody for treatment of T-cell mediated diseases or disorders |
| LT3535392T (lt) | 2016-11-02 | 2024-04-25 | Universität Basel | Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje |
| US12281151B2 (en) | 2018-06-29 | 2025-04-22 | City Of Hope | CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders |
| WO2021138454A1 (en) | 2019-12-30 | 2021-07-08 | City Of Hope | Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers |
-
2019
- 2019-07-01 US US17/256,788 patent/US12281151B2/en active Active
- 2019-07-01 JP JP2021500042A patent/JP7376564B2/ja active Active
- 2019-07-01 AU AU2019295855A patent/AU2019295855B2/en active Active
- 2019-07-01 WO PCT/US2019/040185 patent/WO2020006568A1/en not_active Ceased
- 2019-07-01 EP EP25213534.8A patent/EP4706679A2/en active Pending
- 2019-07-01 CN CN201980055539.8A patent/CN112638478B/zh active Active
- 2019-07-01 ES ES19752576T patent/ES3061216T3/es active Active
- 2019-07-01 EP EP19752576.9A patent/EP3813951B1/en active Active
- 2019-07-01 CN CN202511048418.4A patent/CN120988098A/zh active Pending
-
2025
- 2025-04-14 US US19/178,682 patent/US20250368719A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7550591B2 (ja) | 多重特異的ＮＫｐ４６結合タンパク質 | |
| US20230055445A1 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof | |
| KR102523402B1 (ko) | 이중특이적 체크포인트 억제제 항체 | |
| JP6971153B2 (ja) | 多重特異的ｎｋエンゲイジャータンパク質 | |
| JP7575100B2 (ja) | 免疫細胞活性化のための二重特異性抗体 | |
| JP6702893B2 (ja) | 多重特異的抗原結合タンパク質 | |
| JP7269167B2 (ja) | モジュラー四価二重特異性抗体プラットフォーム | |
| JP2020503015A (ja) | 抗ｃｄ１９のヒト化抗体及びｃｄ１９を標的とする免疫エフェクター細胞 | |
| CA3169601A1 (en) | Bispecific antigen binding molecules targeting ox40 and fap | |
| KR20200085828A (ko) | 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체 | |
| WO2018068182A1 (en) | Novel anti-ctla4 antibodies | |
| CA3131016A1 (en) | Multifunctional molecules that bind to calreticulin and uses thereof | |
| AU2015345024A1 (en) | Antigen binding molecules comprising a TNF family ligand trimer | |
| CN107614013A (zh) | 结合lag‑3的分子和其使用方法 | |
| JP2022542559A5 (cg-RX-API-DMAC7.html) | ||
| WO2022105817A1 (en) | Bi-functional molecules | |
| TW202241956A (zh) | 新穎抗cd24抗體 | |
| US20230416394A1 (en) | Novel conjugate molecules targeting cd39 and tgfbeta | |
| JP2021529539A5 (cg-RX-API-DMAC7.html) |